JSPR

8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

10-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2025 and provided a corporate update. "Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma," said Jeet Mahal, President and Chief Executive Officer of Jasper. "We

UBS resumed coverage of Jasper Therapeutics with a rating of Neutral and set a new price target of $1.50

SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA. 46th Annual TD Cowen Healthcare ConferenceConference Dates: March 2-4, 2026Presentation Date/Time: Monday, March 2, 2026; 3:50 PM ESTPresentation Format: Fireside Chat A live webcast of the f

SCHEDULE 13D/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

Rodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00

8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study BEACON and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026 Company to host conference

8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

Thomas Wiggans appointed Executive Chairperson  Jasper to host an investor webinar on January 8th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced that its Board of Directors has appointed Jeet Mahal as President and Chief Executive Officer

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with drug product utilized Jasper to host conference call and webinar today at 8:00 a.m. ET REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117)

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the Company will host a webinar to present findings from its investigation into the anomalous results from the BEACON study in CSU reported in July, as well as preliminary data from the ETESIAN study in asthma. The webinar will include remarks from Jasper management as well as Dr. Martin Metz, M.D.

SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)